Scholars Central

Conference abstractPublished 15 Aug 2011

Ribophorin II (RPN2) as a novel therapeutic target for cancer stem cells

Authors: Takahiro Ochiya

National Cancer Center Research Institute, Japan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The survival rate for women with advanced, metastatic breast cancer has not changed significantly for decades. Regardless of effective therapies, many women still experience recurrences of breast cancer after treatment. Docetaxel has been shown to be beneficial in the treatment of breast cancer; however, almost half of treated patients do not respond to it and many tumors develop resistance. At present no method exists to predict response to docetaxel or to detect resistance. Moreover, target molecules to increase the efficacy of chemotherapy have not yet been identified. Here we found that inhibition of the ribophorin II (RPN2), a part of oligosaccharyltransferase (OST) complex, promoted docetaxel-dependent apoptosis and inhibited cell growth in a docetaxel-resistant human breast cancer cell line. Silencing of RPN2 resulted in decreased glycosylation and membrane localization of the P-glycoprotein efflux pump, which caused increased sensitization of drug resistant cells to docetaxel (Nat Med, 2008). We also currently found that RPN2 is highly expressed in breast cancer stem cells. Knockdown of RN2 in cancer stem cells by shRPN2 vector system allowed a significant inhibition of cancer growth and lymph node metastasis in vivo. We also found that small non-coding RNA tightly regulates RPN2 gene expression. RPN2 could, therefore, have clinical applications as a target for micromanaging cancer stem cells.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Takahiro Ochiya”